Search

everythinglearnresearchcommunity

for

Search:↓

Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.

A 19-year-old plans to start Dutasteride 0.5mg three times a week to combat genetic alopecia and preserve hair density, with concerns about potential shedding before prom. Users suggest starting the treatment after prom to avoid shedding, and provide advice on where to purchase the medication.

Breezula is seen as potentially overhyped, with concerns about its cost, effectiveness, and long-term benefits compared to existing treatments like finasteride and minoxidil. Some users believe it could complement existing treatments, while others are skeptical about its impact and prefer waiting for newer options like GT20029 and PP405.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

The conversation discusses hair regrowth possibilities using finasteride, minoxidil, microneedling, and dutasteride, with the user experiencing improvement from NW4 to NW2. Achieving NW0 is deemed unrealistic, but further regrowth may be possible with patience and potentially a hair transplant.

The user is struggling to find a reliable source to buy Kirkland Minoxidil in Canada, expressing concerns about the legitimacy of online sellers. They mention skepticism about websites like Kirkland Minoxidil Solution and Zecoya.

A new hair loss treatment reportedly shows a 539% improvement in hair count, but skepticism remains due to unclear placebo results and potential minimal actual hair growth. Many users doubt its effectiveness and market viability, citing high costs and lack of visual proof.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

OP is considering making a 5% topical Clascoterone (Breezula) for hair loss, as they use Minoxidil but can't use Finasteride due to side effects. They seek advice on creating the topical safely, possibly with help from a trained chemist.

The user has been using oral finasteride and minoxidil, along with biotin, vitamin D3, collagen, and micro-needling, to address hair loss over six months. They experienced some shedding initially but have seen progress, with improved hair quality and reduced bald spots.

Hair regrowth and gender transition using finasteride, estrogen, and spironolactone. Significant hair regrowth and personal transformation were achieved through hormone replacement therapy.

Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.

The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.

Peppermint oil may increase hair thickness more effectively than minoxidil, but its effects are mostly studied in animals. Users report mixed results, with some seeing no regrowth and others noting slight improvements when combined with other treatments.

The conversation discusses the potential long-term effects of stopping finasteride after extended use, with differing opinions on the existence and prevalence of post-finasteride syndrome (PFS). Some users report persistent side effects, while others argue that such effects are rare or unrelated to the medication.

Dutasteride 0.5 mg significantly reduces both scalp and hair follicle DHT, with a greater reduction in hair follicle DHT. The discussion questions which reduction is more important for androgenetic alopecia and diffuse thinning.

Oral treatments for hair loss, like Dutasteride and Minoxidil, may be more effective than topical ones, though topical formulations can be similarly effective except for Minoxidil. Topical treatments can be a chore to apply and are often used as supplements to oral treatments.

PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.

The user experienced hair regrowth and thickening after using minoxidil for three months and finasteride for two months, along with vitamin D and iron supplements. They reported softer erections as a side effect of finasteride but found the hair improvements worth it.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

The user experienced hair thinning due to a testosterone spike and used a minoxidil solution and topical finasteride gel. After four months, the gel caused side effects without improving hair thinning, leading to questions about continuing or adjusting the treatment.

Topical Minoxidil may cause pericardial effusion. Caution is advised when using Minoxidil, even topically.

The user has been using oral minoxidil (5mg), finasteride (1mg), and biotin for 4 months with minimal progress in hair regrowth. Other users suggest patience, considering alternative treatments, and note that biotin may not significantly contribute unless there's a deficiency.

The individual is considering starting hair loss treatment with dutasteride, prescribed by a dermatologist, due to concerns about finasteride side effects. They are also interested in the potential benefits of reducing DHT and are contemplating whether to maintain a shaved head or pursue treatment.

The user experienced significant hair regrowth using 1mg finasteride every other day, 5% minoxidil twice daily, and ketoconazole shampoo. The progress was noted as impressive, with some users questioning the authenticity of the results.